ASND vs. BIO: Ascendis Pharma vs. Bio-Rad Laboratories Stock Comparison
How do Ascendis Pharma (ASND) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and Bio-Rad Laboratories (BIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while BIO is classified in Life Sciences Tools & Services.
| Profile Item | ASND | BIO |
|---|---|---|
| Name | Ascendis Pharma A/S | Bio-Rad Laboratories Inc. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 16.90 billion USD | 10.26 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | January 28, 2015 | February 27, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | BIO |
|---|---|---|
| Total Return (1Y) | 29.46% | 28.31% |
| Total Return (3Y, Annualized) | 40.62% | 8.52% |
| Total Return (5Y, Annualized) | 10.03% | -11.74% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | BIO |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 36.50% |
| Beta (5Y) | 0.38 | 1.03 |
| Max Drawdown (5Y) | -55.93% | -72.24% |
| Avg. Volume (3M) | 698.39K | 250.78K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | BIO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | 0.66 |
| Sortino Ratio (1Y) | 0.99 | 0.98 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Ascendis Pharma (ASND) at 118.78% is the standout with ROE above its industry range; Bio-Rad Laboratories (BIO) at 14.27% also sits in the top quartile.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Ascendis Pharma (ASND) at 70.85% and Bio-Rad Laboratories (BIO) at 39.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Ascendis Pharma (ASND) at 64.98% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ASND | BIO |
|---|---|---|
| ROE (TTM) | 118.78% | 14.27% |
| ROA (TTM) | 9.58% | 1.50% |
| Net Margin (TTM) | 70.85% | 39.45% |
| Operating Margin (TTM) | 64.98% | 11.82% |
| Gross Margin (TTM) | 91.30% | 52.19% |
Growth
Revenue Growth
Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Bio-Rad Laboratories (BIO) at 0.65% is closer to the peer norm — faster top-line expansion for ASND.
EPS Growth
Neither Ascendis Pharma (ASND) nor Bio-Rad Laboratories (BIO) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ASND | BIO |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | 0.65% |
| Revenue Growth (3Y CAGR) | 141.43% | -2.68% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Ascendis Pharma (ASND) at 2.99 and Bio-Rad Laboratories (BIO) at 3.18 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Ascendis Pharma (ASND) at 0.31 and Bio-Rad Laboratories (BIO) at 0.18 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ASND | BIO |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 3.18 |
| Debt / Equity (MRQ) | 0.31 | 0.18 |
| Net Debt / EBITDA | -1.37 | -0.73 |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | BIO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Ascendis Pharma (ASND) at 19.68 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Ascendis Pharma (ASND) at 10.45 carries a premium in the upper quartile — a clear price-to-book gap.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
Valuation Metrics
| Metric | ASND | BIO |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | 10.14 |
| P/S Ratio (TTM) | 16.14 | 3.96 |
| P/B Ratio (MRQ) | 10.45 | 1.35 |
| Free Cash Flow Yield (TTM) | 0.08% | 2.65% |